OBJECTIVE: To evaluate (1) levels of the host-defense/antimicrobial peptide LL-37 in patients with trauma and hemorrhagic shock (HS) and (2) the effects of a synthetic host-defense peptide; Pep19-4LF on multiple organ failure (MOF) associated with HS. BACKGROUND: HS is a common cause of death in severely injured patients. There is no specific therapy that reduces HS-associated MOF. METHODS: (1) LL-37 was measured in 47 trauma/HS patients admitted to an urban major trauma center. (2) Male Wistar rats were submitted to HS (90 min, target mean arterial pressure: 27-32 mm Hg) or sham operation. Rats were treated with Pep19-4LF [66 (n = 8) or 333 μg/kg · h (n = 8)] or vehicle (n = 12) for 4 hours following resuscitation. RESULTS: Plasma LL-37 was 12-fold higher in patients with trauma/HS compared to healthy volunteers. HS rats treated with Pep19-4LF (high dose) had a higher mean arterial pressure at the end of the 4-hour resuscitation period (79 ± 4 vs 54 ± 5 mm Hg) and less renal dysfunction, liver injury, and lung inflammation than HS rats treated with vehicle. Pep19-4LF enhanced (kidney/liver) the phosphorylation of (1) protein kinase B and (2) endothelial nitric oxide synthase. Pep19-4LF attenuated the HS-induced (1) translocation of p65 from cytosol to nucleus, (2) phosphorylation of IκB kinase on Ser, and (3) phosphorylation of IκBα on Ser resulting in inhibition of nuclear factor kappa B and formation of proinflammatory cytokines. Pep19-4LF prevented the release of tumor necrosis factor alpha caused by heparan sulfate in human mononuclear cells by binding to this damage-associated molecular pattern. CONCLUSIONS: Trauma-associated HS results in release of LL-37. The synthetic host-defense/antimicrobial peptide Pep19-4LF attenuates the organ injury/dysfunction associated with HS.
OBJECTIVE: To evaluate (1) levels of the host-defense/antimicrobial peptide LL-37 in patients with trauma and hemorrhagic shock (HS) and (2) the effects of a synthetic host-defense peptide; Pep19-4LF on multiple organ failure (MOF) associated with HS. BACKGROUND: HS is a common cause of death in severely injured patients. There is no specific therapy that reduces HS-associated MOF. METHODS: (1) LL-37 was measured in 47 trauma/HS patients admitted to an urban major trauma center. (2) Male Wistar rats were submitted to HS (90 min, target mean arterial pressure: 27-32 mm Hg) or sham operation. Rats were treated with Pep19-4LF [66 (n = 8) or 333 μg/kg · h (n = 8)] or vehicle (n = 12) for 4 hours following resuscitation. RESULTS: Plasma LL-37 was 12-fold higher in patients with trauma/HS compared to healthy volunteers. HS rats treated with Pep19-4LF (high dose) had a higher mean arterial pressure at the end of the 4-hour resuscitation period (79 ± 4 vs 54 ± 5 mm Hg) and less renal dysfunction, liver injury, and lung inflammation than HS rats treated with vehicle. Pep19-4LF enhanced (kidney/liver) the phosphorylation of (1) protein kinase B and (2) endothelial nitric oxide synthase. Pep19-4LF attenuated the HS-induced (1) translocation of p65 from cytosol to nucleus, (2) phosphorylation of IκB kinase on Ser, and (3) phosphorylation of IκBα on Ser resulting in inhibition of nuclear factor kappa B and formation of proinflammatory cytokines. Pep19-4LF prevented the release of tumor necrosis factor alpha caused by heparan sulfate in human mononuclear cells by binding to this damage-associated molecular pattern. CONCLUSIONS:Trauma-associated HS results in release of LL-37. The synthetic host-defense/antimicrobial peptide Pep19-4LF attenuates the organ injury/dysfunction associated with HS.
Authors: Lukas Martin; Alexander Gombert; Jianmin Chen; Julia Liebens; Julia Verleger; Johannes Kalder; Gernot Marx; Michael Jacobs; Christoph Thiemermann; Tobias Schuerholz Journal: Front Immunol Date: 2017-06-12 Impact factor: 7.561
Authors: Gareth S D Purvis; Massimo Collino; Rodrigo A Loiola; Andrea Baragetti; Fausto Chiazza; Martina Brovelli; Madeeha H Sheikh; Debora Collotta; Alessia Cento; Raffaella Mastrocola; Manuela Aragno; Juan C Cutrin; Chris Reutelingsperger; Liliana Grigore; Alberico L Catapano; Magdi M Yaqoob; Giuseppe Danilo Norata; Egle Solito; Christoph Thiemermann Journal: Front Immunol Date: 2019-03-27 Impact factor: 7.561
Authors: Gareth S D Purvis; Fausto Chiazza; Jianmin Chen; Rodrigo Azevedo-Loiola; Lukas Martin; Dennis H M Kusters; Chris Reutelingsperger; Nikolaos Fountoulakis; Luigi Gnudi; Muhammed M Yaqoob; Massimo Collino; Christoph Thiemermann; Egle Solito Journal: Diabetologia Date: 2017-10-30 Impact factor: 10.122
Authors: Nikita M Patel; Noriaki Yamada; Filipe R M B Oliveira; Lara Stiehler; Elisabeth Zechendorf; Daniel Hinkelmann; Sandra Kraemer; Christian Stoppe; Massimo Collino; Debora Collotta; Gustavo Ferreira Alves; Hanna Pillmann Ramos; Regina Sordi; Ingo Marzi; Borna Relja; Gernot Marx; Lukas Martin; Christoph Thiemermann Journal: Front Immunol Date: 2022-04-06 Impact factor: 8.786